Cargando…
Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina
BACKGROUND: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease....
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142788/ https://www.ncbi.nlm.nih.gov/pubmed/35747160 http://dx.doi.org/10.1016/j.eclinm.2022.101358 |
_version_ | 1784715647780913152 |
---|---|
author | Paul, Proma Chandna, Jaya Procter, Simon R. Dangor, Ziyaad Leahy, Shannon Santhanam, Sridhar John, Hima B. Bassat, Quique Bramugy, Justina Bardají, Azucena Abubakar, Amina Nasambu, Carophine Libster, Romina Yanotti, Clara Sánchez Seedat, Farah Horváth-Puhó, Erzsébet Hossain, A.K.M. Tanvir Sadeq-ur Rahman, Qazi Jit, Mark Newton, Charles R. Milner, Kate Gonçalves, Bronner P. Lawn, Joy E. |
author_facet | Paul, Proma Chandna, Jaya Procter, Simon R. Dangor, Ziyaad Leahy, Shannon Santhanam, Sridhar John, Hima B. Bassat, Quique Bramugy, Justina Bardají, Azucena Abubakar, Amina Nasambu, Carophine Libster, Romina Yanotti, Clara Sánchez Seedat, Farah Horváth-Puhó, Erzsébet Hossain, A.K.M. Tanvir Sadeq-ur Rahman, Qazi Jit, Mark Newton, Charles R. Milner, Kate Gonçalves, Bronner P. Lawn, Joy E. |
author_sort | Paul, Proma |
collection | PubMed |
description | BACKGROUND: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. METHODS: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1·5–18 years. Age and sex-matched, children without history of GBS were also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. FINDINGS: Amongst 138 iGBS survivors and 390 non-iGBS children, 38·1% (95% confidence interval [CI]: 30·0% – 46·6%) of iGBS children had any NDI, compared to 21·7% (95% CI: 17·7% - 26·0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15·0% (95% CI: 3·4% - 30·8%) among GBS-meningitis, 5·6% (95% CI: 1·5% - 13·7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 – 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). INTERPRETATION: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. FUNDING: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine. |
format | Online Article Text |
id | pubmed-9142788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91427882022-06-22 Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina Paul, Proma Chandna, Jaya Procter, Simon R. Dangor, Ziyaad Leahy, Shannon Santhanam, Sridhar John, Hima B. Bassat, Quique Bramugy, Justina Bardají, Azucena Abubakar, Amina Nasambu, Carophine Libster, Romina Yanotti, Clara Sánchez Seedat, Farah Horváth-Puhó, Erzsébet Hossain, A.K.M. Tanvir Sadeq-ur Rahman, Qazi Jit, Mark Newton, Charles R. Milner, Kate Gonçalves, Bronner P. Lawn, Joy E. eClinicalMedicine Articles BACKGROUND: Data are limited regarding long-term consequences of invasive GBS (iGBS) disease in early infancy, especially from low- and middle-income countries (LMIC) where most cases occur. We aimed to estimate risk of neurodevelopmental impairment (NDI) in children with a history of iGBS disease. METHODS: A multi-country matched cohort study was undertaken in South Africa, India, Mozambique, Kenya, and Argentina from October 2019 to April 2021. The exposure of interest was defined as a history of iGBS disease (sepsis or meningitis) before 90 days of age, amongst children now aged 1·5–18 years. Age and sex-matched, children without history of GBS were also recruited. Age-appropriate, culturally-adapted assessments were used to define NDI across multiple domains (cognitive, motor, hearing, vision, emotional-behaviour, growth). Pooled NDI risk was meta-analysed across sites. Association of iGBS exposure and NDI outcome was estimated using modified Poisson regression with robust variance estimator. FINDINGS: Amongst 138 iGBS survivors and 390 non-iGBS children, 38·1% (95% confidence interval [CI]: 30·0% – 46·6%) of iGBS children had any NDI, compared to 21·7% (95% CI: 17·7% - 26·0%) of non- iGBS children, with notable between-site heterogeneity. Risk of moderate/severe NDI was 15·0% (95% CI: 3·4% - 30·8%) among GBS-meningitis, 5·6% (95% CI: 1·5% - 13·7%) for GBS-sepsis survivors. The adjusted risk ratio (aRR) for moderate/severe NDI among iGBS survivors was 1.27 (95% CI: 0.65, 2.45), when compared to non-GBS children. Mild impairment was more frequent in iGBS (27.6% (95% CI: 20.3 – 35.5%)) compared to non-GBS children (12.9% (95% CI: 9.7% - 16.4%)). The risk of emotional-behavioural problems was similar irrespective of iGBS exposure (aRR=0.98 (95% CI: 0.55, 1.77)). INTERPRETATION: Our findings suggest that iGBS disease is on average associated with a higher risk of moderate/severe NDI, however substantial variation in risk was observed between sites and data are consistent with a wide range of values. Our study underlines the importance of long-term follow-up for at-risk neonates and more feasible, standardised assessments to facilitate diagnosis in research and clinical practice. FUNDING: This work was supported by a grant (INV-009018) from the Bill & Melinda Gates Foundation to the London School of Hygiene &Tropical Medicine. Elsevier 2022-04-28 /pmc/articles/PMC9142788/ /pubmed/35747160 http://dx.doi.org/10.1016/j.eclinm.2022.101358 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Paul, Proma Chandna, Jaya Procter, Simon R. Dangor, Ziyaad Leahy, Shannon Santhanam, Sridhar John, Hima B. Bassat, Quique Bramugy, Justina Bardají, Azucena Abubakar, Amina Nasambu, Carophine Libster, Romina Yanotti, Clara Sánchez Seedat, Farah Horváth-Puhó, Erzsébet Hossain, A.K.M. Tanvir Sadeq-ur Rahman, Qazi Jit, Mark Newton, Charles R. Milner, Kate Gonçalves, Bronner P. Lawn, Joy E. Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina |
title | Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina |
title_full | Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina |
title_fullStr | Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina |
title_full_unstemmed | Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina |
title_short | Neurodevelopmental and growth outcomes after invasive Group B Streptococcus in early infancy: A multi-country matched cohort study in South Africa, Mozambique, India, Kenya, and Argentina |
title_sort | neurodevelopmental and growth outcomes after invasive group b streptococcus in early infancy: a multi-country matched cohort study in south africa, mozambique, india, kenya, and argentina |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142788/ https://www.ncbi.nlm.nih.gov/pubmed/35747160 http://dx.doi.org/10.1016/j.eclinm.2022.101358 |
work_keys_str_mv | AT paulproma neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT chandnajaya neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT proctersimonr neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT dangorziyaad neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT leahyshannon neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT santhanamsridhar neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT johnhimab neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT bassatquique neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT bramugyjustina neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT bardajiazucena neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT abubakaramina neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT nasambucarophine neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT libsterromina neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT yanotticlarasanchez neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT seedatfarah neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT horvathpuhoerzsebet neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT hossainakmtanvir neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT sadequrrahmanqazi neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT jitmark neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT newtoncharlesr neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT milnerkate neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT goncalvesbronnerp neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT lawnjoye neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina AT neurodevelopmentalandgrowthoutcomesafterinvasivegroupbstreptococcusinearlyinfancyamulticountrymatchedcohortstudyinsouthafricamozambiqueindiakenyaandargentina |